What is HC Wainwright’s Forecast for KALV FY2030 Earnings?

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) – Research analysts at HC Wainwright issued their FY2030 EPS estimates for KalVista Pharmaceuticals in a research note issued to investors on Friday, January 9th. HC Wainwright analyst A. Fein expects that the specialty pharmaceutical company will post earnings of $5.90 per share for the year. HC Wainwright currently has a “Buy” rating and a $37.00 target price on the stock. The consensus estimate for KalVista Pharmaceuticals’ current full-year earnings is ($3.56) per share.

KalVista Pharmaceuticals (NASDAQ:KALV) last announced its earnings results on Monday, November 10th. The specialty pharmaceutical company reported ($0.92) EPS for the quarter, topping the consensus estimate of ($0.96) by $0.04. The firm had revenue of $13.69 million during the quarter, compared to the consensus estimate of $6.03 million.

Other analysts also recently issued research reports about the company. Citizens Jmp decreased their target price on KalVista Pharmaceuticals from $29.00 to $28.00 and set a “market outperform” rating for the company in a research note on Tuesday, November 11th. Citigroup reiterated a “market outperform” rating on shares of KalVista Pharmaceuticals in a report on Tuesday, November 11th. Needham & Company LLC raised their price objective on shares of KalVista Pharmaceuticals from $28.00 to $32.00 and gave the stock a “buy” rating in a research note on Tuesday, January 6th. Wall Street Zen raised shares of KalVista Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, December 6th. Finally, Cowen reissued a “buy” rating on shares of KalVista Pharmaceuticals in a report on Wednesday, December 3rd. Eight investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, KalVista Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus price target of $29.17.

KalVista Pharmaceuticals Trading Up 6.2%

Shares of NASDAQ:KALV opened at $16.80 on Monday. The company has a debt-to-equity ratio of 8.18, a quick ratio of 7.21 and a current ratio of 7.22. The stock’s 50-day moving average is $14.57 and its 200-day moving average is $13.61. The company has a market cap of $849.17 million, a P/E ratio of -4.25 and a beta of -0.14. KalVista Pharmaceuticals has a 52-week low of $7.30 and a 52-week high of $19.00.

Institutional Trading of KalVista Pharmaceuticals

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Vanguard Group Inc. lifted its stake in KalVista Pharmaceuticals by 3.7% during the third quarter. Vanguard Group Inc. now owns 2,501,119 shares of the specialty pharmaceutical company’s stock worth $30,464,000 after purchasing an additional 88,720 shares during the period. Tudor Investment Corp ET AL bought a new stake in shares of KalVista Pharmaceuticals in the 3rd quarter valued at approximately $24,360,000. Parkman Healthcare Partners LLC raised its holdings in shares of KalVista Pharmaceuticals by 155.5% in the 3rd quarter. Parkman Healthcare Partners LLC now owns 1,735,003 shares of the specialty pharmaceutical company’s stock worth $21,132,000 after buying an additional 1,055,940 shares in the last quarter. Emerald Advisers LLC lifted its position in shares of KalVista Pharmaceuticals by 30.2% during the 3rd quarter. Emerald Advisers LLC now owns 1,351,254 shares of the specialty pharmaceutical company’s stock worth $16,458,000 after buying an additional 313,205 shares during the period. Finally, Schroder Investment Management Group boosted its stake in KalVista Pharmaceuticals by 108.7% in the 3rd quarter. Schroder Investment Management Group now owns 1,158,457 shares of the specialty pharmaceutical company’s stock valued at $14,145,000 after buying an additional 603,499 shares in the last quarter.

Insider Activity

In related news, insider Paul K. Audhya sold 5,296 shares of the firm’s stock in a transaction on Monday, November 24th. The stock was sold at an average price of $13.45, for a total value of $71,231.20. Following the completion of the transaction, the insider directly owned 131,831 shares of the company’s stock, valued at $1,773,126.95. This trade represents a 3.86% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Benjamin L. Palleiko sold 7,294 shares of KalVista Pharmaceuticals stock in a transaction on Monday, December 8th. The stock was sold at an average price of $16.51, for a total transaction of $120,423.94. Following the sale, the chief executive officer owned 424,520 shares in the company, valued at $7,008,825.20. This represents a 1.69% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 31,329 shares of company stock worth $437,371. Company insiders own 4.30% of the company’s stock.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals is a clinical‐stage biotechnology company focused on the discovery and development of small‐molecule protease inhibitors for orphan and specialty disease indications. The firm’s scientific platform centers on selective inhibition of plasma kallikrein, a serine protease implicated in disorders characterized by vascular leak, edema and inflammation. KalVista’s approach leverages oral and intravitreal delivery formats to target both systemic and ophthalmic conditions.

The company’s lead programs include an oral plasma kallikrein inhibitor in clinical trials for the acute treatment of hereditary angioedema (HAE) attacks and an intravitreal kallikrein inhibitor being evaluated for diabetic macular edema.